Published in PLoS One on May 17, 2013
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Copy number variation detection and genotyping from exome sequence data. Genome Res (2012) 4.44
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet (2011) 3.82
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood (2006) 1.94
A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet (2009) 1.78
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost (2011) 1.73
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem (2012) 1.45
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin? BMC Genet (2009) 1.34
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost (2008) 1.11
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (2011) 1.07
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost (2010) 1.02
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood (2008) 1.00
Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost (2008) 0.97
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics (2011) 0.95
The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost (2007) 0.87
10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics (2009) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86
A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One (2010) 0.85
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica (2009) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
[Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol (2002) 1.44
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
[Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev Esp Cardiol (2007) 1.13
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Rev Esp Cardiol (2004) 1.08
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer (2004) 1.03
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol (2006) 1.03
Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfus Apher Sci (2007) 1.02
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2004) 1.01
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol (2005) 0.98
Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. Haematologica (2006) 0.97
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Thrombosis as a conformational disease. Haematologica (2005) 0.93
Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica (2011) 0.93
Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica (2005) 0.93
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood (2007) 0.92
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res (2008) 0.92
Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood (2012) 0.92
Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol (2007) 0.92
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest (2008) 0.92
Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica (2009) 0.91
L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica (2010) 0.91
Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica (2010) 0.90
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. Am Heart J (2004) 0.90
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol (2010) 0.90
Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica (2008) 0.89
Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol (2007) 0.89
Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiat Prot Dosimetry (2007) 0.89
Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation (2004) 0.88
Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res Treat (2003) 0.88
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) (2012) 0.87
Treatment of the open abdomen with topical negative pressure therapy: a retrospective study of 46 cases. Int Wound J (2011) 0.87
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost (2014) 0.86
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica (2007) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab (2014) 0.85
Safety evaluation and nutritional composition of a Fraxinus excelsior seed extract, FraxiPure™. Food Chem Toxicol (2012) 0.85
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica (2010) 0.85
[Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]. Gac Sanit (2011) 0.85
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol (2005) 0.85
Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. Eur J Haematol (2013) 0.84
Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb Haemost (2010) 0.84
Regulatory regions of SERPINC1 gene: identification of the first mutation associated with antithrombin deficiency. Thromb Haemost (2012) 0.84
Home treatment of uncomplicated acute diverticulitis. Int Surg (2012) 0.84
[Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?]. Med Clin (Barc) (2011) 0.83
Potential role of miRNAs in developmental haemostasis. PLoS One (2011) 0.83
Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol (2004) 0.83
Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke (2014) 0.82
Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. J Lab Clin Med (2003) 0.82
Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem (2009) 0.82
Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist (2013) 0.82
Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. Br J Haematol (2005) 0.81
GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet J Rare Dis (2013) 0.81